Literature DB >> 33513745

The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction.

Pavel Vodicka1,2,3, Ladislav Andera4,5, Alena Opattova1,2,3, Ludmila Vodickova1,2,3.   

Abstract

The disruption of genomic integrity due to the accumulation of various kinds of DNA damage, deficient DNA repair capacity, and telomere shortening constitute the hallmarks of malignant diseases. DNA damage response (DDR) is a signaling network to process DNA damage with importance for both cancer development and chemotherapy outcome. DDR represents the complex events that detect DNA lesions and activate signaling networks (cell cycle checkpoint induction, DNA repair, and induction of cell death). TP53, the guardian of the genome, governs the cell response, resulting in cell cycle arrest, DNA damage repair, apoptosis, and senescence. The mutational status of TP53 has an impact on DDR, and somatic mutations in this gene represent one of the critical events in human carcinogenesis. Telomere dysfunction in cells that lack p53-mediated surveillance of genomic integrity along with the involvement of DNA repair in telomeric DNA regions leads to genomic instability. While the role of individual players (DDR, telomere homeostasis, and TP53) in human cancers has attracted attention for some time, there is insufficient understanding of the interactions between these pathways. Since solid cancer is a complex and multifactorial disease with considerable inter- and intra-tumor heterogeneity, we mainly dedicated this review to the interactions of DNA repair, telomere homeostasis, and TP53 mutational status, in relation to (a) cancer risk, (b) cancer progression, and (c) cancer therapy.

Entities:  

Keywords:  DNA damage response; TP53 mutational status; cancer progression; cancer risk; cancer therapy; interactions; telomere homeostasis

Year:  2021        PMID: 33513745     DOI: 10.3390/cancers13030479

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  8 in total

Review 1.  [Advances in research of Musashi2 in solid tumors].

Authors:  Y Yang; M Zhao; T Ding; C Ni; Q Zheng; X Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-03-20

2.  Age at first birth and lung cancer: a two-sample Mendelian randomization study.

Authors:  Haoxin Peng; Xiangrong Wu; Yaokai Wen; Xiaoqin Du; Caichen Li; Hengrui Liang; Jinsheng Lin; Jun Liu; Fan Ge; Zhenyu Huo; Jianxing He; Wenhua Liang
Journal:  Transl Lung Cancer Res       Date:  2021-04

3.  Lung Fibroblasts from Idiopathic Pulmonary Fibrosis Patients Harbor Short and Unstable Telomeres Leading to Chromosomal Instability.

Authors:  Radhia M'Kacher; Madeleine Jaillet; Bruno Colicchio; Eirini Vasarmidi; Arnaud Mailleux; Alain Dieterlen; Caroline Kannengiesser; Claire Borie; Noufissa Oudrhiri; Steffen Junker; Philippe Voisin; Eric Jeandidier; Patrice Carde; Michael Fenech; Annelise Bennaceur-Griscelli; Bruno Crestani; Raphael Borie
Journal:  Biomedicines       Date:  2022-01-28

Review 4.  Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response.

Authors:  Mateusz Kciuk; Adrianna Gielecińska; Somdutt Mujwar; Mariusz Mojzych; Renata Kontek
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

5.  Detection of disease-causing mutations in prostate cancer by NGS sequencing.

Authors:  Alessandra Mangolini; Christian Rocca; Cristian Bassi; Carmelo Ippolito; Massimo Negrini; Lucio Dell'Atti; Giovanni Lanza; Roberta Gafà; Nicoletta Bianchi; Paolo Pinton; Gianluca Aguiari
Journal:  Cell Biol Int       Date:  2022-04-06       Impact factor: 4.473

Review 6.  The potential interplay between G-quadruplex and p53: their roles in regulation of ferroptosis in cancer.

Authors:  Lulu Zhang; Yi Lu; Xiaoli Ma; Yuanxin Xing; Jinbo Sun; Yanfei Jia
Journal:  Front Mol Biosci       Date:  2022-07-25

7.  Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer.

Authors:  Ildikó Kocsmár; Éva Kocsmár; Gábor Pajor; Janina Kulka; Eszter Székely; Glen Kristiansen; Oliver Schilling; Péter Nyirády; András Kiss; Zsuzsa Schaff; Péter Riesz; Gábor Lotz
Journal:  Cancers (Basel)       Date:  2022-09-21       Impact factor: 6.575

8.  A cohesin-associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma.

Authors:  Cui-Zhen Liu; Jian-Di Li; Gang Chen; Rong-Quan He; Rui Lin; Zhi-Guang Huang; Jian-Jun Li; Xiu-Fang Du; Xiao-Ping Lv
Journal:  FEBS Open Bio       Date:  2022-09-02       Impact factor: 2.792

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.